MarketCap
Facebook
X
Telegram
QIAGEN N.V. Gross Profit | QGEN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 967 M | 1.23 B | 1.38 B | 1.45 B | 1.23 B | 1.01 B | 1 B | 923 M | 845 M | 826 M | 865 M | 815 M | 824 M | 750 M | 716 M | 667 M | 600 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 B | 600 M | 967 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accelerate Diagnostics
AXDX
|
2.7 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 328.03 | -0.28 % | $ 27.3 B | USA |
 |
Lantheus Holdings
LNTH
|
942 M | $ 99.94 | 0.14 % | $ 6.74 B | USA |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 666.34 | -0.24 % | $ 34.3 B |  Schweiz |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.82 | 0.42 % | $ 3.79 M | USA |
 |
NeoGenomics
NEO
|
314 M | $ 16.7 | 0.63 % | $ 2.14 B | USA |
 |
Neogen Corporation
NEOG
|
408 M | $ 12.22 | 0.21 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
81.5 M | $ 22.54 | 2.78 % | $ 505 M | USA |
 |
Natera
NTRA
|
127 M | $ 404.77 | 0.2 % | $ 55.3 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
403 M | $ 11.74 | -0.68 % | $ 123 M |  China |
 |
OPKO Health
OPK
|
206 M | $ 1.63 | 1.23 % | $ 1.22 B | USA |
 |
Trinity Biotech plc
TRIB
|
21.4 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
T2 Biosystems
TTOO
|
-3.15 M | - | -39.35 % | $ 313 K | USA |
 |
Bioventus
BVS
|
388 M | $ 14.75 | -1.44 % | $ 983 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Precipio
PRPO
|
10.7 M | $ 19.5 | -2.55 % | $ 31.3 M | USA |
 |
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
RadNet
RDNT
|
154 M | $ 69.9 | -0.63 % | $ 5.26 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 26.55 | -1.28 % | $ 25.2 B |  Niderland |
 |
Senseonics Holdings
SENS
|
15.8 M | $ 7.46 | -0.67 % | $ 311 M | USA |
 |
Sotera Health Company
SHC
|
646 M | $ 18.35 | 1.35 % | $ 5.21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
11.3 B | $ 684.39 | 1.57 % | $ 258 B | USA |
 |
Twist Bioscience Corporation
TWST
|
6.96 M | $ 145.39 | 3.91 % | $ 8.7 B | USA |
 |
Waters Corporation
WAT
|
1.4 B | $ 456.36 | 0.39 % | $ 27.2 B | USA |
 |
Exagen
XGN
|
38.8 M | $ 7.44 | 2.34 % | $ 160 M | USA |
 |
Quotient Limited
QTNT
|
14.9 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
33.6 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
4.42 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K |  Israel |
 |
Castle Biosciences
CSTL
|
53 M | $ 32.84 | -0.73 % | $ 952 M | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
156 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
7.1 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
188 M | - | - | $ 1.49 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 69.1 | -0.17 % | $ 3.68 B | USA |
 |
Co-Diagnostics
CODX
|
400 K | $ 0.55 | 0.4 % | $ 732 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
3.66 B | $ 242.85 | 0.4 % | $ 27 B | USA |
 |
Danaher Corporation
DHR
|
14.5 B | $ 232.83 | 1.01 % | $ 166 B | USA |
 |
DexCom
DXCM
|
2.8 B | $ 77.9 | -0.05 % | $ 30.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 183.8 | -0.79 % | $ 14.4 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
2.66 B | $ 568.9 | 1.52 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
2.87 B | $ 268.6 | -0.3 % | $ 41.6 B | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 273.81 | -1.99 % | $ 47.1 B | USA |